Open in app

Nasal Covid vaccination from AstraZeneca is not as effective as anticipated: study

img-1
Total Views:
136
img-1
Total Likes:
1
img-1
Published By:
Peeyush Ghalot
img-1
Published On:
14-10-2022

AstraZeneca's intranasal administered COVID-19 vaccine did not perform as expected in a small study published on Tuesday, suggesting there may be difficulties in making nasal sprays a reliable option. The Covid nasal spray developed by Oxford University and AstraZeneca did not perform as well as expected. A small percentage of participants in a Phase 1 clinical trial that was reported in the journal eBioMedicine developed mucosal antibody responses. Intranasal vaccination also resulted in poorer systemic immune responses than intramuscular vaccination, which involve many other immune cells, according to the study's authors. The vaccine utilized in the trial, which was created in partnership with the University of Oxford and is already licensed for use by injection and based on the ChAdOx1 adenovirus vector, was used as well. The ChAdOx1 vector used in the vaccine is an adenovirus that causes the common cold but has been genetically altered such that it cannot multiply in people. The most recent study is expected to be the first to publish information on the use of a straightforward nasal spray to administer an adenovirus-vectored vaccine. A initial dose of the intranasal vaccine was administered to 30 previously unvaccinated study participants. The researchers also looked into the viability of using an intranasal vaccine as a booster. The intranasal vaccine was given to 12 subjects who had previously undergone a typical two-dose COVID-19 vaccination schedule via injection. According to the study, neither a persistent mucosal antibody nor potent systemic immune responses were produced by the vaccine. The researchers noted that no significant adverse events or safety issues were reported throughout the trial. According to Associate Professor Sandy Douglas, Chief Investigator of the experiment at the University of Oxford, "The nasal spray did not do as well in this study as we had planned."

Reference: - https://economictimes.indiatimes.com/industry/healthcare/biotech/healthcare/covid-nasal-spray-by-oxford-university-and-astrazeneca-not-as-effective-as-expected-study-shows/articleshow/94792124.cms?from=mdr